Covid-19 All the details of the vaccination of children
The Pfizer
vaccine
is much less effective in children between the ages of 5 and 11 when it comes to preventing the spread of
Covid
than in older children and adults, although it does work when it comes to preventing the most serious effects of the virus.
The conclusion comes from a study led by six researchers from
the New York Department of Health
that opens the door to modifying the dose in this population group, a third with respect to those over 12 years of age.
The report, carried out between December 13 and January 20, reflects how the effectiveness of the vaccine against the spread of the coronavirus went from 66% to 51% in young people between 12 and 17 years old in that period of time, a percentage which
decreased to 12%
in the case of children aged 5 to 11 years.
It is a step backwards for both the pharmaceutical company and parents in the United States, since it is the only vaccine available for that age at the national level.
The results make it clear that
protection against infection is almost nil
even one month after receiving the full regimen.
Eli Rosenberg
, deputy director of the New York State Department of Health and the person leading the study, said she was disappointed but not entirely surprised "since it's a vaccine developed for a previous variant," not for omicron, the dominant one during the period in which the tests were carried out.
The key seems to lie in the dose, from the 30 micrograms assigned for children over 12 years of age to the
10 micrograms
that it was decided to give to those between 5 and 12 years of age.
The possibility of collecting more information and changing the approach remains open despite the pronounced decrease in positives at the national level and the lesser effect of the coronavirus on children.
On Monday the numbers spoke of an average of 65,000 positives nationwide -62% more than two weeks ago-, 1,876 deaths per day on average, and close to breaking the barrier of 50,000 hospitalized by Covid throughout the country, far from 156,000 registered at the beginning of the year.
The data in the report is
in line with that of clinical trials conducted in children 2 to 4 years
of age.
They were disappointing with a dose even lower than the population group between 5 and 12 years.
They also coincide with the announcement of the Centers for Disease Control and Prevention (CDC) on Friday that eliminates the obligation to wear masks in schools in areas with low risk of contagion.
The problem with the possible increase in dosage is the side effects that could occur, including constant fevers.
The other route would be a third booster dose, currently being tested by Pfizer, an option that has been shown to be effective in adults.
Conforms to The Trust Project criteria
Know more
Coronavirus
United States
CDC
covid 19
SaludPfizer requests approval for its pediatric vaccine against coronavirus in children under 5 years of age
Crisis Emmanuel Macron reaches out to Vladimir Putin in Moscow to "start a de-escalation"
HealthThe EMA approves the Moderna vaccine for children between 6 and 11 years old
See links of interest
Ukraine
Foster children Ukraine
Last News
Topics
Work calendar 2022
Time change
best colleges
Atalanta - Sampdoria
Granada CF - Cadiz
Malaga - FC Cartagena